TG Therapeutics TGTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $461.9M+1,080% | $447.18M+1,812% | $447.47M— | $60.46M— | $39.15M— | ||
| $83K+76.6% | $59K-13.2% | $47K-51.5% | $41K-74.2% | $47K-72.7% | ||
| $69.65M+44.6% | $64.67M+52.0% | $60.97M+52.5% | $55.05M+47.2% | $48.17M+19.1% | ||
| —— | —— | —— | —— | —— | ||
| $1.2M-27.9% | $1.22M-39.0% | $1.22M-47.9% | $1.33M-48.2% | $1.66M-35.1% | ||
| $201.93M+61.4% | $176.44M+126% | $149.66M+95.9% | $147.91M+124% | $125.14M+122% | ||
| —— | —— | —— | —— | $76.23M+62.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$1.47M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.34M+227% | -$298K+60.5% | -$366K-44.7% | -$861K-384% | -$1.05M-640% | ||
| $1.87M-4.0% | $1.75M-8.0% | $1.81M-4.1% | $1.88M+0.1% | $1.95M+3.6% | ||
| —— | —— | —— | —— | -$3.46M— | ||
| -$1.98M+15.2% | -$2.1M+12.1% | -$2.18M+8.7% | -$2.26M+5.2% | -$2.34M+1.8% | ||
| $27.14M— | $42.43M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $240K+243% | $214K+376% | $168K+600% | $112K— | $70K— | ||
| $168.35M-47.0% | $237.5M-23.6% | $281.2M+7.8% | $295.75M+52.0% | $317.9M+107% | ||
| —— | —— | —— | —— | —— | ||
| $151.24M-52.9% | $222.24M-28.4% | $234.56M-26.9% | $304.61M+10.4% | $321.04M+55.7% | ||
| —— | —— | —— | —— | —— | ||
| $185.11M+1,144% | $91.24M+942% | $97.85M+4,453% | $21.76M— | $14.88M— | ||
| —— | —— | —— | —— | —— | ||
| $742K+6,645% | $0— | $453K— | $453K+45,200% | $11K-100.0% | ||
| —— | —— | —— | —— | —— | ||
| $306.14M+138% | -$90.79M-167% | -$90.79M-167% | $121.91M+21,439% | $128.49M+171% | ||
| $305.04M— | -$105.78M— | —— | —— | —— | ||
| $20.49M-7.6% | $24.25M+31.3% | $24.76M+46.6% | $25.77M+164% | $22.17M+134% | ||
| $11.32M— | $7.88M— | $7.53M— | $5.58M— | —— | ||
| $1.2M-27.9% | $1.22M-39.0% | $1.22M-47.9% | $1.33M-48.2% | $1.66M-35.1% | ||
| —— | —— | —— | —— | —— | ||
| -$1.98M+15.2% | -$2.1M+12.1% | -$2.18M+8.7% | -$2.26M+5.2% | -$2.34M+1.8% | ||
| $27.14M— | $42.43M— | —— | —— | —— | ||
| —— | —— | -$1.47M— | —— | —— | ||
| —— | $6.17M— | $4.63M— | $3.09M— | $1.54M— | ||
| $2.82M-57.6% | $3.79M-45.8% | $5.1M-25.2% | $6.13M+17.5% | $6.65M+84.5% | ||
| $1.87M-4.0% | $1.75M-8.0% | $1.81M-4.1% | $1.88M+0.1% | $1.95M+3.6% | ||
| —— | —— | —— | —— | —— | ||
| $151.24M-52.9% | $222.24M-28.4% | $234.56M-26.9% | $304.61M+10.4% | $321.04M+55.7% | ||
| $185.11M+1,144% | $91.24M+942% | $97.85M+4,453% | $21.76M— | $14.88M— | ||
| —— | —— | —— | —— | —— | ||
| $185K-10.6% | $185K-12.7% | $192K-9.4% | $200K-5.7% | $207K-2.4% | ||
| —— | —— | —— | —— | -$552K-2,805% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| —— | —— | —— | —— | -$80.66M— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| $11.32M— | $7.88M— | $7.53M— | $5.58M— | —— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does TG Therapeutics generate?
- TG Therapeutics (TGTX) generated -$95.4M in operating cash flow over the trailing twelve months.
- What is TG Therapeutics's free cash flow?
- After $240.0K of capital expenditures, TG Therapeutics's free cash flow was -$95.6M over the trailing twelve months, down 66.2% year over year.
- Where does TG Therapeutics's cash flow data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
